Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 10160–10162.

https://doi.org/10.1182/blood-2022-157347

Published: 2022

Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2021) 138 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2021-146047

Published: 2021

Journal Articles

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

David Taft, Clark Henderson, Christine O'Day, Changpu Yu, Hong Li, Phoenix Ho, Heather Van Epps

Blood (2021) 138 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2021-150866

Published: 2021

Journal Articles

Potential of Sea-CD70 for the Treatment of Myeloid Leukemia

Daniel Diolaiti, PhD, Jane Haass, Michelle Ulrich, Yufei Chen, PhD, Phoenix Ho, MD, Shyra J Gardai, PhD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-140829

Published: 2020

Journal Articles

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Ahmed Aribi, MD, Anjali S Advani, MD, William Donnellan, MD, Amir T. Fathi, MD, Marcello Rotta, MD, Benjamin K. Tomlinson, MD, Pankit Vachani, MD, Jay Yang, MD, Phoenix Ho, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136203

Published: 2020

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

C. Michel Zwaan, MD PhD, Stefan Söderhäll, MD PhD, Benoit Brethon, MD, Matteo Luciani, MD, Carmelo Rizzari, MD, David Sternberg, MD PhD, Emmanuelle Besse, Catherine Dutreix, MD, Franca Fagioli, MD, Phoenix Ho, MD, Carlo Dufour, MD, Rob Pieters, MD PhD

Blood (2015) 126 (23): 2564.

https://doi.org/10.1182/blood.V126.23.2564.2564

Published: 2015

Journal Articles

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Kristen Miller, BS, Phoenix Ho, MD, Nyla A. Heerema, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 2614.

https://doi.org/10.1182/blood.V114.22.2614.2614

Published: 2009

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, PhD, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Beverly Lange, MD, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 143.

https://doi.org/10.1182/blood.V112.11.143.143

Published: 2008

Journal Articles

CEBPA Mutations Predict Favorable Prognosis in Pediatric AML

Phoenix Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica A. Pollard, Derek Stirewalt, Craig Alan Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet Franklin, Jerald Radich, Soheil Meshinchi

Blood (2008) 112 (11): 142.

https://doi.org/10.1182/blood.V112.11.142.142

Published: 2008

NARROW

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

Potential of Sea-CD70 for the Treatment of Myeloid Leukemia

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

CEBPA Mutations Predict Favorable Prognosis in Pediatric AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only